Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register account icon
S&P 500
7,580.06
(
0.22%
)
US TECH 100
29,630.00
(
0.33%
)
Dow Jones
51,032.46
(
0.72%
)
Brent Oil
93.65
(
2.51%
)
Bitcoin
72,940.59
(
-0.84%
)
News Focus
News Focus
Post# of 9090
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (4) Keep Next 10 Report Keyboard Shortcuts
Replies (4) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 123040
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jmkobers post# 829

Friday, 05/17/2019 3:47:12 PM

Friday, May 17, 2019 3:47:12 PM

Post# of 9090
There are already two phase-3 CD trials in progress…

Efficacy (ASPEN-1)—placebo comparator; 300 patients; single-injection; 36w observation; expected completion Sep 2020:
https://www.clinicaltrials.gov/ct2/show/NCT03608397

Open-label safety (ASPEN-OLS)—350 patients including rollovers from ASPEN-1; multiple-injection; 52w observation; expected completion Nov 2021:
https://www.clinicaltrials.gov/ct2/show/NCT03617367

See #msg-146260318 for related info.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (4) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (4) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote